Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H22O5 |
Molecular Weight | 354.3964 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C(=O)\C=C\C2=CC=C(O)C=C2)C(O)=C(CC=C(C)C)C(O)=C1
InChI
InChIKey=ORXQGKIUCDPEAJ-YRNVUSSQSA-N
InChI=1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+
Molecular Formula | C21H22O5 |
Molecular Weight | 354.3964 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Xanthohumol is a prenylated flavonoid most abundant in hops. It is found in beers and refreshment drinks. It can attenuate several factors of the metabolic syndrome. It has been reported to inhibit adipogenesis or increase cell apoptosis and therefore can be used in preventing obesity. Xanthohumol inhibited angiogenesis by suppressing NF-κB activity in pancreatic cancer. Xanthohumol may represent a novel therapeutic agent for the management of pancreatic cancer. Moreover, it is in phase I clinical trials for preventing many types of cancer. It has a range of other biological properties: antiviral, antimalarial, antibacterial and as an osteoporosis preventing agent.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5077 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20387235 |
44.57 µM [IC50] | ||
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20387235 |
7.19 µM [IC50] | ||
Target ID: WP408 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.3 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
25 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
37 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
9.7 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
63 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
70 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
83 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
178 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
342 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
511 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
982 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
216 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
286.99 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
354 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
712 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
996 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
22 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
21.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
ISOXANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
16 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24038952 |
180 mg single, oral dose: 180 mg route of administration: Oral experiment type: SINGLE co-administered: |
XANTHOHUMOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. | 2005 Sep |
|
Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells. | 2013 Dec |
|
Curcumin analogue identified as hyaluronan export inhibitor by virtual docking to the ABC transporter MRP5. | 2013 Dec |
|
Xanthohumol induces phase II enzymes via Nrf2 in human hepatocytes in vitro. | 2013 Feb |
|
Xanthohumol attenuates tumour cell-mediated breaching of the lymphendothelial barrier and prevents intravasation and metastasis. | 2013 Jul |
|
2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. | 2013 May 25 |
|
Induction of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) by Glycyrrhiza Species Used for Women's Health: Differential Effects of the Michael Acceptors Isoliquiritigenin and Licochalcone A. | 2015 Nov 16 |
|
Xanthohumol inhibits cell cycle progression and proliferation of larynx cancer cells in vitro. | 2015 Oct 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01367431
Single dose of 20 mg, 60mg, or 180 mg over a course of six days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28960474
Xanthohumol showed strong antimicrobial effects with MIC and MBC values of 15-107 ug/mL, which are close to those of conventional antibiotics in the strains of Clostridium difficile bacteria with increased resistance.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:59:00 GMT 2023
by
admin
on
Fri Dec 15 18:59:00 GMT 2023
|
Record UNII |
T4467YT1NT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C274
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
||
|
DSLD |
3469 (Number of products:3)
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
639665
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
DB15359
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
XANTHOHUMOL
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
C121950
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
6754-58-1
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
T4467YT1NT
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
134289
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
DTXSID00893171
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY | |||
|
C104536
Created by
admin on Fri Dec 15 18:59:00 GMT 2023 , Edited by admin on Fri Dec 15 18:59:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |